Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Bemnifosbuvir

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Atea Presents Bemnifosbuvir + Ruzasvir DDI Data at EASL
    Atea Presents Bemnifosbuvir + Ruzasvir DDI Data at EASL

    27 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/27/3301752/0/en/atea-pharmaceuticals-presents-new-drug-drug-interaction-results-supporting-potential-best-in-class-profile-of-the-regimen-of-bemnifosbuvir-and-ruzasvir-for-the-treatment-of-hepatit.html

    GLOBENEWSWIRE
    27 May 2026
    Share Share
    Atea Pharma Showcases Viral Hepatitis Pipeline Progress At EASL
    Atea Pharma Showcases Viral Hepatitis Pipeline Progress At EASL

    13 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/13/3293835/0/en/atea-pharmaceuticals-to-present-three-abstracts-at-easl-2026-congress-highlighting-progress-across-viral-hepatitis-pipeline.html

    GLOBENEWSWIRE
    13 May 2026
    Share Share
    Atea Pharma Reveals Q3 2025 Financials & Business Update
    Atea Pharma Reveals Q3 2025 Financials & Business Update

    12 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/12/3186782/0/en/Atea-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    12 Nov 2025
    Share Share
    Atea Reports Data For Bemnifosbuvir + Ruzasvir At Liver Meeting
    Atea Reports Data For Bemnifosbuvir + Ruzasvir At Liver Meeting

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183594/0/en/Atea-Pharmaceuticals-Presents-New-Data-Supporting-the-Fixed-Dose-Combination-of-Bemnifosbuvir-and-Ruzasvir-as-a-Potential-Best-in-Class-Regimen-for-Treatment-of-Hepatitis-C-Virus-I.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    Atea To Present Bemnifosbuvir + Ruzasvir Data For Hepatitis C
    Atea To Present Bemnifosbuvir + Ruzasvir Data For Hepatitis C

    07 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/07/3162443/0/en/Atea-Pharmaceuticals-to-Present-New-Data-Supporting-Combination-of-Bemnifosbuvir-and-Ruzasvir-as-Potential-Best-in-Class-Regimen-for-Treatment-of-Hepatitis-C-Virus-Infection-at-The.html

    GLOBENEWSWIRE
    07 Oct 2025
    Share Share
    Atea Presents Full Phase 2 Data on Hep C Combo at EASL 2025
    Atea Presents Full Phase 2 Data on Hep C Combo at EASL 2025

    07 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/07/3075940/0/en/Atea-Pharmaceuticals-Announces-Full-Results-from-Phase-2-Study-of-Regimen-of-Bemnifosbuvir-and-Ruzasvir-for-Treatment-of-Hepatitis-C-Virus-HCV-Presented-at-EASL-Congress-2025.html

    GLOBENEWSWIRE
    07 May 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.